WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2001000807) MUTATED Nurr1 GENE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/000807    International Application No.:    PCT/SE2000/001380
Publication Date: 04.01.2001 International Filing Date: 29.06.2000
Chapter 2 Demand Filed:    29.01.2001    
C07K 14/705 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE) (For All Designated States Except US).
BUERVENICH, Silvia [DE/SE]; (SE) (For US Only).
OLSON, Lars [SE/SE]; (SE) (For US Only).
ANVRET, Maria [SE/SE]; (SE) (For US Only).
CARMINE, Andrea [SE/SE]; (SE) (For US Only)
Inventors: BUERVENICH, Silvia; (SE).
OLSON, Lars; (SE).
ANVRET, Maria; (SE).
CARMINE, Andrea; (SE)
Agent: ASTRAZENECA AB; R&D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE)
Priority Data:
9902489-5 30.06.1999 SE
Abstract: front page image
(EN)The present invention relates to an isolated Nurr1 gene including one or more mutations selected from the group consisting of Met97Val (M97V), His103Arg (H103R), Tyr121del (Y121del) and Tyr122del (Y122del), or a functional fragment or variant thereof, as well as to proteins or peptides encoded thereof. Further, the invention also relates to cell cultures and transgenic animals comprising a mutated gene or a gene fragment as models for the study of psychotic disorders, such as schizophrenia and/or manic depressive disorder, as well as for the identification of effective therapies and drugs for the treatment of said disorders. In an additional aspect the invention relates to novel drugs developed by use of one or more of the mutations according to the invention for the treatment and/or prevention of psychotic disorders. Finally, the invention relates to methods of diagnostis wherein the mutations according to the invention are identified as well as to kits for performing such methods.
(FR)La présente invention concerne un gène Nurr1 isolé présentant une ou plusieurs mutations sélectionnées dans le groupe comprenant Met97Val (M97V), His103Arg (H103R), Tyr121del (Y121del) et Tyr122del (Y122del), ou un fragment ou un allèle fonctionnel dudit gène, ainsi que des protéines ou des peptides codés par ledit gène. En outre, l'invention concerne des cultures de cellules et des animaux transgéniques comprenant un gène ou un fragment de gène muté, que l'on utilise comme modèles pour l'étude des troubles psychotiques, tels que la schizophrénie et/ou les troubles maniaco-dépressifs, et pour l'identification de thérapies et de médicaments efficaces pour le traitement de ces troubles. Un autre aspect de l'invention concerne de nouveaux médicaments destinés au traitement et/ou à la prévention des troubles psychotiques, lesquels médicaments ont été mis au point par l'utilisation d'une ou de plusieurs mutations selon l'invention. Enfin, l'invention concerne des méthodes de diagnostic basées sur l'identification des mutation selon l'invention, ainsi que des kits permettant de mettre en oeuvre ces méthodes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)